Compare SFST & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SFST | EOLS |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 579.0M | 529.1M |
| IPO Year | 2012 | 2018 |
| Metric | SFST | EOLS |
|---|---|---|
| Price | $59.89 | $7.76 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $68.50 | $15.00 |
| AVG Volume (30 Days) | 67.8K | ★ 612.3K |
| Earning Date | 10-27-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.76 | 1.23 |
| EPS | ★ 2.39 | N/A |
| Revenue | $6,282,000.00 | ★ $297,176,000.00 |
| Revenue This Year | $23.97 | $12.44 |
| Revenue Next Year | $17.69 | $17.37 |
| P/E Ratio | $25.27 | ★ N/A |
| Revenue Growth | ★ 12.99 | 11.61 |
| 52 Week Low | $40.90 | $3.86 |
| 52 Week High | $65.09 | $9.31 |
| Indicator | SFST | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 42.29 | 47.04 |
| Support Level | $59.26 | $7.59 |
| Resistance Level | $61.69 | $8.47 |
| Average True Range (ATR) | 1.10 | 0.32 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 45.76 | 46.18 |
Southern First Bancshares Inc is a bank holding company. Through its banking subsidiary, it is engaged in the business of accepting demand deposits and savings deposits insured by the Federal Deposit Insurance Corporation (the FDIC), and providing commercial, consumer, and mortgage loans, ATM processing, and other banking products and services to the general public. The group operates through various retail offices located in the Greenville, Columbia, and Charleston markets of South Carolina, three retail offices in the Raleigh, Greensboro, and Charlotte markets of North Carolina, and one retail office in Atlanta, Georgia.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.